Sienna appoints new director

Latest News

Sienna Cancer Diagnostics (ASX:SDX) has announced the appointment of Helen Fisher as an independent non-executive director and chair of its audit and risk committee effective 28 March 2018.

The company's chair, Geoff Cumming, said: “We are very pleased to welcome Helen to Sienna’s Board. She brings great financial acumen, including accounting and taxation expertise, which, combined with her deep knowledge of the Life Sciences industry and her extensive network in the investment community, make Helen a valuable addition to our Board.”

Previously, as a partner at Deloitte for ten years, Ms Fisher led its life sciences industry team and advised many life sciences and biotechnology companies.

In July 2017, Ms Fisher established a new global life sciences fund, Bio Capital Impact Fund, investing in disruptive, high-growth companies. She has also advised on the effective tax management of intellectual property, mergers, acquisitions and product licensing, all areas relevant to Sienna.

“I am delighted to join Sienna’s Board and look forward to contributing to the worldwide commercialisation of the Company’s technology and working alongside Sienna’s team in growing the Company,” said Ms Fisher.